Replies to post #63951 on SOHM Inc (SHMN)

[Myth]

ABBIE is currently undergoing further development to optimize expression and purification of its protein-based platform. Upon completion of development, ABBIE will become high-quality, off-the-shelf cell engineering kits. Gene-editing companies will use ABBIE kits to deliver a gene payload to a specific locus on their targeted cells.

Revenue generations can be obtained immediately through licensing and gene-editing kits slated to be released for commercialization in 3Q/4Q 2024. ABBIE is expected to reach in-human trial on or before 4Q 2025.

Would it really be wise to tell the competitors how Abbie is " different ", especially before the Patent is granted ?